News
Browse all news articles and resources.
Why 'Good Enough' Depression Care Is No Longer Enough
New clinical guidance pushes for true remission in treatment-resistant depression. Here's what that means for patients exploring ketamine therapy.
BPL-003 Trial Results: What They Mean for TRD Patients
New phase 2a data on BPL-003 shows lasting depression symptom reduction. Here's what it means for patients exploring ketamine and emerging TRD therapies.
New PTSD Prevention Drug Trial: What Patients Should Know
A new DoD-backed trial is testing BXCL501 for acute stress reactions. Here's what it means for ketamine patients pursuing PTSD treatment today.
Beyond 'Less Bad': New Push for True TRD Remission
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for patients and ketamine therapy in 2026.
Glutamate Treatments Reshape TRD Care in 2026
New research confirms glutamate-based treatments like esketamine offer fast relief for treatment-resistant depression. Here's what it means for online ketamine care.